THE SILVERSTEIN FOUNDATION

The Silverstein Foundation for Parkinson's with GBA actively pursues and invests in cutting edge research with the goal of discovering new therapies for the treatment of Parkinson's Disease in glucocerebrosidase (GBA) mutation carriers. Read more about our foundation and our mission... The GBA gene (Glucosylceramidase Beta Acid) encodes the protein glucocerebrosidase, or GCase. GCase functions to allow a brain cell to clear debris via a cellular component known as the lysosome. Those who have mutations in the GBA gene are at higher risk for Parkinson's Disease (PD) because they have a reduction in GCase activity and can't effectively remove the debris. It is hypothesized that this excess debris aggregates, causing clumps of alpha synuclein, which is toxic to brain cells... The percentage of patients that have Parkinson's with GBA is believed to be roughly 7-10% of the overall Parkinson's population, however therapeutic breakthroughs identified through our work have the potential to..

Primary location: New York United States